Crossmark

Vineland Adaptive Behavior Scale in a Cohort of Four ADNP Syndrome Patients Implicates Age-Dependent Developmental Delays with Increased Impact of Activities of Daily Living

Crossref DOI link: https://doi.org/10.1007/s12031-022-02048-0

Published Online: 2022-08-03

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Levine, Joseph

Hakim, Fahed

Kooy, R. Frank

Gozes, Illana
License Information

Text and Data Mining valid from 2022-08-01

Version of Record valid from 2022-08-01
More Information

Article History

Received: 1 July 2022

Accepted: 7 July 2022

First Online: 3 August 2022

Declarations

:

: Professor Illana Gozes is a co-founder, a director and Chief Scientific Officer at ATED Therapeutics LTD, developing Davunetide for the ADNP syndrome. NAP (CP201, davunetide) use is under patent protection (US patent nos. US7960334, US8618043, and USWO2017130190A1) (IG), PCT/IL2020/051010 (IG) and provisional patent applications been submitted.

Document is current

Any future updates will be listed below